Executive
|
Center for Health Information and Analysis (CHIA)
|
Discussions with the HPC and/or Advisory Council and CHIA with a focus on health care price variation, gross and net Rx drug costs to the state, as well as the establishment and implementation of Accountable Care Organizations (ACO’s).
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
614
|
An Act to help patients and reduce healthcare costs by ensuring patient adherence to medications
|
Support
|
$0.00
|
N/A
|
House Bill
|
3551
|
An Act to promote transparency and cost control of pharmaceutical drug prices
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
1013
|
An Act relative to pharmaceutical gag clauses
|
Neutral
|
$0.00
|
N/A
|
Executive
|
MassHealth
|
MassHealth Prescription Drug Pricing FY20 H.1 Proposal
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
915
|
An Act ensuring access to medications
|
Support
|
$0.00
|
N/A
|
House Bill
|
3800
|
An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
712
|
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
733
|
An Act relative to consumer protection for prescription drug purchases
|
Neutral
|
$0.00
|
N/A
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Promoted and assisted with information pertaining to the HPC study on the use of Prescription Drug coupons and vouchers.
|
Support
|
$0.00
|
N/A
|
House Bill
|
926
|
An Act relative to consumer deductibles
|
Support
|
$0.00
|
N/A
|
House Bill
|
1117
|
An Act relative to drug prices paid by carriers
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
721
|
An Act relative to mandatory prescription drug coverage
|
Oppose
|
$0.00
|
N/A
|
Senate Docket
|
2415
|
FY2020 Budget
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
916
|
An Act relative to co-pay assistance
|
Support
|
$0.00
|
N/A
|
House Bill
|
629
|
An Act relative to pharmaceutical pricing
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
717
|
An Act to create a special commission to improve transparency and affordability at the Group Insurance Commission
|
Oppose
|
$0.00
|
N/A
|
Executive
|
Executive Office of Health and Human Services (EOHHS)
|
Engaged in discussions related to the proposed rules for 101 CMR 801.00
|
Neutral
|
$0.00
|
N/A
|
House Bill
|
1178
|
An Act relative to promoting transparency in the pharmaceutical industry
|
Support
|
$0.00
|
N/A
|
House Bill
|
1162
|
An Act to promote transparency in prescription drug prices
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
1701
|
An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
3800
|
An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements
|
Support
|
$0.00
|
N/A
|
House Bill
|
4134
|
An Act to Improve Health care by investing in VALUE
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
703
|
An Act to define modest meals and refreshments in prescriber education settings
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
1193
|
An Act providing for the establishment of a drug cost review commission
|
Neutral
|
$0.00
|
N/A
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Participate in public meetings/discussions pertaining to drug costs (net and gross), value-based contracts with health plans and the HPC, potential drug company testimony at the annual HPC Cost Trends Hearings. Promoted the overall clinical value of precription medicines and the economic impact of the biotechnology sector in the Commonwealth.
|
Support
|
$0.00
|
N/A
|
House Bill
|
1099
|
An Act to help patients and reduce health care costs by ensuring patient adherence to medications
|
Support
|
$0.00
|
N/A
|
House Bill
|
1154
|
An Act to reduce drug costs through transparency
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
1352
|
An Act establishing a special commission to study and recommend improvements in the delivery of prescription drug benefits for the citizens of the Commonwealth
|
Oppose
|
$0.00
|
N/A
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Engaged in discussions related to proposed drug pricing review regulations 958 CMR 12.00.
|
Neutral
|
$0.00
|
N/A
|
House Bill
|
1853
|
An Act relative to fail first and patient safety
|
Support
|
$0.00
|
N/A
|
House Bill
|
1167
|
An Act relative to prescription drug price transparency
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
3800
|
An Act making appropriations for the fiscal year 2020 for the maintenance of the departments, boards, commissions, institutions and certain activities of the commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements
|
Neutral
|
$0.00
|
N/A
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Direct involvement with the State’s Health Policy Commission (HPC) as a formal member of the Health Policy Commission’s (HPC) Advisory Council in discussions to implement the MA Health Care Cost Containment Law (Chapter 224).
|
Neutral
|
$0.00
|
N/A
|
House Bill
|
3481
|
An Act to ensure the fair, transparent and patient-focused use of health technology assessments by the Commonwealth
|
Support
|
$0.00
|
N/A
|
House Bill
|
1193
|
An Act providing for the establishment of a drug cost review commission
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
931
|
An Act promoting high value and high quality care
|
Neutral
|
$0.00
|
N/A
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Interactions with the Health Policy Commission and participation in the HPC Advisory Council to include tours of the R&D facilities in Norwood and Waltham, MA.
|
Support
|
$0.00
|
N/A
|
House Bill
|
969
|
An Act empowering health care consumers
|
Support
|
$0.00
|
N/A
|
House Bill
|
1148
|
An Act regarding Massachusetts drug price relief
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
1304
|
An Act to restore integrity in the marketing of pharmaceutical products and medical devices
|
Oppose
|
$0.00
|
N/A
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Discussions with the HPC and/or Advisory Council and CHIA with a focus on health care price variation, gross and net Rx drug costs to the state, as well as the establishment and implementation of Accountable Care Organizations (ACO’s).
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
541
|
An Act relative to co-pay assistance
|
Support
|
$0.00
|
N/A
|
House Bill
|
1972
|
An Act to permit the wholesale importation of prescription drugs into the Commonwealth
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
966
|
An Act to promote value-based insurance design in the Commonwealth
|
Neutral
|
$0.00
|
N/A
|
Executive
|
Center for Health Information and Analysis (CHIA)
|
Planning and executing executive & legislative tours at our corporate research & development laboratory/campus in the Commonwealth of MA in Waltham. Also, planned and executed an R&D tour of laboratory space in Norwood, MA.
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
1235
|
An Act relative to step therapy and patient safety
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
695
|
An Act to improve the accessibility and affordability of pharmaceutical drugs of public health concern
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
1177
|
An Act relative to protecting health care consumers
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
2397
|
An Act relative to pharmaceutical access, costs and transparency
|
Support
|
$0.00
|
N/A
|
Senate Docket
|
2415
|
FY2020 Budget
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
696
|
An Act to promote transparency and cost control of pharmaceutical drug prices
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
1186
|
An Act strengthening HPC and CHIA market oversight
|
Neutral
|
$0.00
|
N/A
|
Executive
|
Massachusetts Health Policy Commission (HPC)
|
Planning and executing executive & legislative tours at our corporate research & development laboratory/campus in the Commonwealth of MA in Waltham. Also, planned and executed an R&D tour of laboratory space in Norwood, MA.
|
Neutral
|
$0.00
|
N/A
|
Senate Bill
|
1206
|
An Act to ensure the fair, transparent and patient-focused use of health technology assessments by the Commonwealth
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
552
|
An Act to promote transparency in prescription drug prices
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
1168
|
An Act establishing a commission to review contracts between pharmaceutical benefit managers and MassHealth
|
Neutral
|
$0.00
|
N/A
|
House Bill
|
3504
|
An Act making appropriations for the fiscal year 2019 to provide for supplementing certain existing appropriations and for certain other activities and projects
|
Support
|
$0.00
|
N/A
|
House Bill
|
949
|
An Act relative to non-medical switching
|
Support
|
$0.00
|
N/A
|
House Bill
|
1133
|
An Act to ensure prescription drug cost transparency and affordability
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
1301
|
An Act to prevent undue influence on prescriber behavior
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
4134
|
An Act to improve health care by investing in VALUE
|
Oppose
|
$0.00
|
N/A
|
House Bill
|
898
|
An Act relative to consumer deductibles
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
2397
|
An Act Relative to Pharmaceutical Access, Cost and Transparency
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
706
|
An Act to ensure prescription drug cost transparency and affordability
|
Oppose
|
$0.00
|
N/A
|
Senate Bill
|
652
|
An Act relative to pharmaceutical gag clauses
|
Neutral
|
$0.00
|
N/A
|
| | |
Total amount
|
$0.00
| |